The Microbiome in Advanced Melanoma: Where Are We Now?

[1]  Yue Li,et al.  Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events , 2023, Frontiers in Immunology.

[2]  N. Segata,et al.  Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma , 2023, JAMA oncology.

[3]  C. Huttenhower,et al.  Microbiome epidemiology and association studies in human health , 2022, Nature Reviews Genetics.

[4]  S. Khanna,et al.  Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection , 2022, Drugs.

[5]  N. Ajami,et al.  Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome , 2022, Nature Medicine.

[6]  E. Miyauchi,et al.  The impact of the gut microbiome on extra-intestinal autoimmune diseases , 2022, Nature Reviews Immunology.

[7]  F. Shanahan,et al.  The gut microbiome as a modulator of healthy ageing , 2022, Nature Reviews Gastroenterology & Hepatology.

[8]  Jun Yu,et al.  Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes , 2022, Gut.

[9]  J. Badger,et al.  Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 , 2022, Nature Medicine.

[10]  Jeff Trent,et al.  Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial , 2022, Nature Medicine.

[11]  T. Spector,et al.  Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma , 2022, Nature Medicine.

[12]  D. Haller,et al.  Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders , 2022, Nature Reviews Gastroenterology & Hepatology.

[13]  E. Pamer,et al.  Microbiome-based therapeutics , 2022, Nature Reviews Microbiology.

[14]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[15]  Jared C Malke,et al.  Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response , 2021, Science.

[16]  J. Raes,et al.  Temporal variability in quantitative human gut microbiome profiles and implications for clinical research , 2021, Nature Communications.

[17]  R. Hayes,et al.  Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma , 2021, Genome medicine.

[18]  A. Awasthi,et al.  High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity , 2021, Science advances.

[19]  Depei Wu,et al.  Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial , 2021, Frontiers in Immunology.

[20]  D. Farmakiotis,et al.  Antibiotic use is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[21]  R. Weichselbaum,et al.  Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade , 2021, Gut.

[22]  J. Badger,et al.  Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients , 2021, Science.

[23]  T. Spector,et al.  Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade , 2020, JCI insight.

[24]  N. Ajami,et al.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients , 2020, Science.

[25]  J. Nielsen,et al.  Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma , 2020, JCI insight.

[26]  T. Gajewski,et al.  Cancer and the Microbiome: Influence of the commensal microbiota on cancer, immune responses, and immunotherapy. , 2020, Gastroenterology.

[27]  K. Köhrer,et al.  An intact gut microbiome protects genetically predisposed mice against leukemia. , 2020, Blood.

[28]  Z. Szallasi,et al.  Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage , 2020, Science.

[29]  K. Honda,et al.  Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? , 2020, Nature Reviews Immunology.

[30]  Jingyuan Fu,et al.  Interaction between drugs and the gut microbiome , 2020, Gut.

[31]  David R. Bell,et al.  Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. , 2020, JCI insight.

[32]  W. Xu,et al.  Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. , 2020, Journal of the National Cancer Institute.

[33]  David B. Darr,et al.  Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy , 2020, Proceedings of the National Academy of Sciences.

[34]  Thomas D. Wu,et al.  Peripheral T cell expansion predicts tumour infiltration and clinical response , 2020, Nature.

[35]  A. Iglesias-Santamaría.  Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer , 2020, Clinical and Translational Oncology.

[36]  Piyushkumar A. Mundra,et al.  Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy , 2019, Nature Cancer.

[37]  S. Steck,et al.  Dietary patterns and cancer risk , 2019, Nature Reviews Cancer.

[38]  P. Klenerman,et al.  Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma , 2019, Nature Medicine.

[39]  D. Pe’er,et al.  Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies , 2019, Proceedings of the National Academy of Sciences.

[40]  I. Osman,et al.  Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients , 2019, Genome Medicine.

[41]  D. Carbone,et al.  Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications , 2019, BMC Cancer.

[42]  C. Brock,et al.  Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. , 2019, JAMA oncology.

[43]  S. Turner,et al.  Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells. , 2019, Immunity.

[44]  Christine B. Peterson,et al.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes , 2019, Cell.

[45]  Jennifer M. Fettweis,et al.  The Integrative Human Microbiome Project , 2019, Nature.

[46]  B. Kan,et al.  Gut microbiota community characteristics and disease-related microorganism pattern in a population of healthy Chinese people , 2019, Scientific Reports.

[47]  M. Meyerson,et al.  Commensal Microbiota Promote Lung Cancer Development via γδ T Cells , 2019, Cell.

[48]  G. Linette,et al.  A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.

[49]  D. Plichta,et al.  A defined commensal consortium elicits CD8 T cells and anti-cancer immunity , 2019, Nature.

[50]  C. Jobin,et al.  Microbiota and cancer immunotherapy: in search of microbial signals , 2018, Gut.

[51]  B. Helmink,et al.  Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.

[52]  S. Hazen,et al.  Dietary metabolism, the gut microbiome, and heart failure , 2018, Nature Reviews Cardiology.

[53]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[54]  J. Lapek,et al.  Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer , 2018, Cell.

[55]  S. Guglielmetti,et al.  Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. , 2018, Cell reports.

[56]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  Casey M. Theriot,et al.  Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells , 2018, Science.

[58]  Vu Dinh,et al.  Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host , 2018, Nature.

[59]  Maria E. Kempner,et al.  Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. , 2018, Blood advances.

[60]  L. Tordesillas,et al.  Mechanisms of Oral Tolerance , 2018, Clinical Reviews in Allergy & Immunology.

[61]  A. Quest,et al.  Helicobacter pylori and Gastric Cancer: Adaptive Cellular Mechanisms Involved in Disease Progression , 2018, Front. Microbiol..

[62]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[63]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[64]  Donna Neuberg,et al.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.

[65]  Peter K. Sorger,et al.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.

[66]  Rabi Yacoub,et al.  Lupus: The microbiome angle. , 2017, Immunobiology.

[67]  E. Frenkel,et al.  Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients , 2017, Neoplasia.

[68]  Fangfang Guo,et al.  Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy , 2017, Cell.

[69]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[71]  C. Drake,et al.  LAG3 (CD223) as a cancer immunotherapy target , 2017, Immunological reviews.

[72]  F. Bäckhed,et al.  Role of gut microbiota in atherosclerosis , 2017, Nature Reviews Cardiology.

[73]  P. Rosenstiel,et al.  Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. , 2016, Immunity.

[74]  Y. Taur,et al.  Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice , 2016, Science Translational Medicine.

[75]  Morris A. Swertz,et al.  Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity , 2016, Science.

[76]  J. Raes,et al.  Population-level analysis of gut microbiome variation , 2016, Science.

[77]  C. Huttenhower,et al.  Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis , 2016, Nature Communications.

[78]  G. Cresci,et al.  Gut Microbiome: What We Do and Don't Know. , 2015, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[79]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[80]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[81]  F. Bäckhed,et al.  Normalization of Host Intestinal Mucus Layers Requires Long-Term Microbial Colonization. , 2015, Cell host & microbe.

[82]  Y. Taur,et al.  Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[83]  J. Beniak,et al.  Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. , 2015, Complementary therapies in medicine.

[84]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[85]  S. Jonjić,et al.  Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. , 2015, Immunity.

[86]  K.,et al.  Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. , 2015, American journal of preventive medicine.

[87]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[88]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[89]  A. Viale,et al.  The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. , 2014, Blood.

[90]  Yan Wang,et al.  The role of microbiome in central nervous system disorders , 2014, Brain, Behavior, and Immunity.

[91]  Daniel Wolff,et al.  Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[92]  M. Ebert,et al.  Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[93]  F. Marincola,et al.  Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.

[94]  M. R. Rubinstein,et al.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. , 2013, Cell host & microbe.

[95]  Liping Zhao.  The gut microbiota and obesity: from correlation to causality , 2013, Nature Reviews Microbiology.

[96]  N. Socci,et al.  Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[98]  R. Khanin,et al.  Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation , 2012, The Journal of experimental medicine.

[99]  Raul Rabadan,et al.  Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. , 2012, Cancer cell.

[100]  J. Clemente,et al.  Human gut microbiome viewed across age and geography , 2012, Nature.

[101]  T. Borody,et al.  Fecal microbiota transplantation and emerging applications , 2012, Nature Reviews Gastroenterology &Hepatology.

[102]  T. Okazaki,et al.  PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice , 2011, The Journal of experimental medicine.

[103]  Matthew R. Redinbo,et al.  Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme , 2010, Science.

[104]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[105]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[106]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[107]  A. Stringer,et al.  Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats , 2008, Cancer biology & therapy.

[108]  S. Duncan,et al.  Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria. , 2008, FEMS microbiology ecology.

[109]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[110]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[111]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[112]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[113]  P. Linsley,et al.  CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics , 1997, The Journal of experimental medicine.

[114]  U. Stenram,et al.  The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. , 1996, Gastroenterology.

[115]  U. Stenram,et al.  Pectin-supplemented enteral diet reduces the severity of methotrexate induced enterocolitis in rats. , 1996, Scandinavian journal of gastroenterology.

[116]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[117]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[118]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[119]  G. Freeman,et al.  Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. , 1993, Science.

[120]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[121]  P. Linsley,et al.  T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[122]  S. Roman-Roman,et al.  LAG-3, a novel lymphocyte activation gene closely related to CD4 , 1990, The Journal of experimental medicine.

[123]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[124]  P. Lorigan,et al.  Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. , 2019, The oncologist.